<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00903799</url>
  </required_header>
  <id_info>
    <org_study_id>2008/046/HP</org_study_id>
    <nct_id>NCT00903799</nct_id>
  </id_info>
  <brief_title>Medico-economic Evaluation of ENTERRA Therapy</brief_title>
  <acronym>ENTERRA</acronym>
  <official_title>Clinical Efficacy and Efficiency of Gastric Electrical Stimulation (Enterra®) for Refractory Nausea and/or Vomiting</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Rouen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Rouen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this clinical trial is to assess the symptomatic efficacy and the impact on the&#xD;
      utilization of healthcare resources of a treatment by gastric electrical stimulation (ENTERRA&#xD;
      ®) in patients with refractory nausea and/or vomiting leading to a nutritional impairment.&#xD;
      Eligible patients will be those with refractory symptoms either idiopathic, postsurgical or&#xD;
      due to diabetes mellitus. The duration of the study will be 28 months for each patient.&#xD;
&#xD;
      After a run-in period of 4 months during which a prospective assessment of healthcare&#xD;
      resources utilization and of the severity of the symptoms will be obtained, patients will be&#xD;
      implanted. The follow-up period after implantation of the device will last 24 months in every&#xD;
      patients and will be divided in two parts: a) After the first postoperative month during&#xD;
      which the device will remained on the &quot;OFF&quot; position, the first phase of the study will be a&#xD;
      randomized double-blind cross-over study with 2 periods of 4 months during which the device&#xD;
      will be activated or not. After the 9th month of follow up, the trial will be an open trial&#xD;
      and the device will be activated in all patients.&#xD;
&#xD;
      During the whole trial, patients will record all types of healthcare resources utilizations&#xD;
      (hospitalizations, drug treatments, endoscopic procedures…) while the symptomatic efficacy of&#xD;
      the treatment will be assessed by standard questionnaires at the following visits scheduled&#xD;
      at 1, 5, 9, 12, 18, 24 months. The glycemic control will be determined at each visit in&#xD;
      diabetic patients. A delayed gastric emptying will not be a selection criteria but we have&#xD;
      planned to analyze the clinical results of the treatment in taking into account a delayed or&#xD;
      normal gastric emptying during the pre-implantation period. Moreover, gastric emptying&#xD;
      studies have been scheduled at 5, 9, 12 and 24 months to test the impact of gastric&#xD;
      electrical stimulation on gastric emptying.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>clinical efficacy</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>medico-economic evaluation of ENTERRA therapy</measure>
    <time_frame>28 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">220</enrollment>
  <condition>Gastroparesis</condition>
  <condition>Vomiting</condition>
  <condition>Nausea</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Gastric electrical stimulation using Enterra Therapy. Device activated during 4 months then device in 'OFF' position the 4 following months.&#xD;
After the cross-over period, device activated until the end of the trial</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Gastric electrical stimulation using Enterra Therapy. Device in 'OFF' position during 4 months then device activated the 4 following months.&#xD;
After the cross-over period, device activated until the end of the trial</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Implantation of ENTERRA therapy</intervention_name>
    <description>Gastric electrical stimulation using Enterra Therapy</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Nausea and/or vomiting refractory to prokinetics and antiemetics fulfilling the following&#xD;
        criteria&#xD;
&#xD;
          1. Due to diabetes mellitus type 1, secondary to oesogastric surgery (vagotomy, partial&#xD;
             gastric resection) or idiopathic&#xD;
&#xD;
          2. Non related to other cause&#xD;
&#xD;
          3. Chronic (duration &gt; 12 months)&#xD;
&#xD;
          4. Occurring at least weekly&#xD;
&#xD;
          5. Refractory to anti-emetics (chlorpromazine, ondansétron, granisétron) and/or&#xD;
             prokinetics (domperidone, metoclopramide, erythromycin),&#xD;
&#xD;
          6. Leading to weight loss or significant reduction of food intake&#xD;
&#xD;
          7. occurring in patients without any contra-indication for the surgical implantation of&#xD;
             the device, in particular severe cardiac or respiratory failure or haemostasis&#xD;
             disorders,&#xD;
&#xD;
          8. in patients older than 18 years&#xD;
&#xD;
          9. with a negative pregnancy test at entry into the trial in women&#xD;
&#xD;
         10. Patients who signed the study consentment&#xD;
&#xD;
         11. Affiliation to the the welfare system&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients older than 70,&#xD;
&#xD;
          2. Patients in whom nausea and/or vomiting are related to another aetiology than that&#xD;
             previously described.&#xD;
&#xD;
          3. Patients with an absolute contraindication for general anaethesia and surgery&#xD;
&#xD;
          4. Patients with a contra-indication for implantation of the device&#xD;
&#xD;
          5. Patients with a severe psychiatric disorder&#xD;
&#xD;
          6. Patients under guardianship or curatorship&#xD;
&#xD;
          7. Patients with a major obesity or as severe eating disorder.&#xD;
&#xD;
          8. Patients unable to understand French.&#xD;
&#xD;
          9. Pregnant women or nursing mothers&#xD;
&#xD;
         10. Lack of effective contraception&#xD;
&#xD;
         11. Patients having undergone a pancreatic graft within the previous 6 months and being in&#xD;
             a unstable clinical conditions at enrollment&#xD;
&#xD;
         12. Patients with an underlying disease leading to a follow-up by MRI&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe DUCROTTE, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>UH Rouen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UH Besancon</name>
      <address>
        <city>Besancon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP-HP Jean Verdier</name>
      <address>
        <city>Bondy</city>
        <zip>93143</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UH Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UH Clermont Ferrand</name>
      <address>
        <city>Clermont Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP-HP Louis Mourier</name>
      <address>
        <city>Colombes</city>
        <zip>92071</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Corbeil Essones Hospital</name>
      <address>
        <city>Corbeil-Essonnes</city>
        <zip>91106</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UH Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UH Lille</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UH Lyon</name>
      <address>
        <city>Lyon</city>
        <zip>69000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UH Marseille</name>
      <address>
        <city>Marseille</city>
        <zip>13000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UH Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UH Nancy</name>
      <address>
        <city>Nancy</city>
        <zip>54000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UH Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UH Nice</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UH Nimes</name>
      <address>
        <city>Nimes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UH Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UH Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UH Rouen</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UH Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UH Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31075</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UH Tours</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <study_first_submitted>May 14, 2009</study_first_submitted>
  <study_first_submitted_qc>May 14, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 18, 2009</study_first_posted>
  <last_update_submitted>May 25, 2016</last_update_submitted>
  <last_update_submitted_qc>May 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug-refractory gastroparesis</keyword>
  <keyword>diabetes mellitus induced gastroparesis</keyword>
  <keyword>Gastric electrical stimulation</keyword>
  <keyword>Long-term multicenter study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroparesis</mesh_term>
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

